Don’t Let NIH Be Dragged Into Applied Research, Outgoing Director Cautions
This article was originally published in The Pink Sheet Daily
Executive Summary
Zerhouni says the agency needs to stay focused on "the fundamental understanding of biological systems," calls for a better technology transfer system to get discoveries to industry.
You may also be interested in...
Deals Of The Week: Academic Drug-Discovery Group’s Work Catching Industry’s Notice
As academic labs fill gaps in discovery work once performed by biopharma companies, Roche is confident that a U.S. consortium of academic drug-discovery units will lead to broader partnerships between industry and academia and within the academy itself. Plus, MedImmune acquires ADC specialist Spirogen and other deals from the past week.
BIO Teams With Zerhouni On Quest For "New Big Ideas" To Speed Development
BIO CEO Jim Greenwood is looking for "new big ideas" that would enable the pharmaceutical industry "to accelerate the pace of progress from academic research and translational research into products.
BIO Teams With Zerhouni On Quest For "New Big Ideas" To Speed Development
BIO CEO Jim Greenwood is looking for "new big ideas" that would enable the pharmaceutical industry "to accelerate the pace of progress from academic research and translational research into products.